These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 34750764)

  • 1. Targeting Cyclic Guanylate Monophosphate in Resistant Hypertension and Heart Failure: Are Sacubitril/Valsartan and Vericiguat Synergistic and Effective in Both Conditions?
    Gallo G; Rubattu S; Volpe M
    High Blood Press Cardiovasc Prev; 2021 Nov; 28(6):541-545. PubMed ID: 34750764
    [No Abstract]   [Full Text] [Related]  

  • 2. Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients.
    Butt JH; McMurray JJV
    Eur J Heart Fail; 2022 Sep; 24(9):1623-1624. PubMed ID: 35919944
    [No Abstract]   [Full Text] [Related]  

  • 3. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
    Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ESC Guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy.
    Crea F
    Eur Heart J; 2021 Sep; 42(36):3581-3585. PubMed ID: 34549264
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative efficacy of vericiguat to sacubitril/valsartan for patients with heart failure reduced ejection fraction: Systematic review and network meta-analysis.
    Kang DW; Kang SH; Lee K; Nam K; Kim ES; Yoon JC; Park SK
    Int J Cardiol; 2024 Apr; 400():131786. PubMed ID: 38242507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry.
    Pierce JB; Li Z; Greiner MA; Lippmann SJ; Hardy NC; Shen X; Stampehl M; Mentz RJ; Allen LA; Peterson PN; Fonarow GC; O'Brien EC; Greene SJ
    Circ Heart Fail; 2023 Jan; 16(1):e010176. PubMed ID: 36314141
    [No Abstract]   [Full Text] [Related]  

  • 8. Characteristics of patients hospitalized for acute heart failure and discharged from an emergency medicine ward with sacubitril-valsartan: differences with patients in the PIONEER-HF and TRANSITION studies.
    Gabrielli M; Romani GR; Franceschi F
    J Cardiovasc Med (Hagerstown); 2023 Mar; 24(3):203-205. PubMed ID: 36724400
    [No Abstract]   [Full Text] [Related]  

  • 9. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
    Kario K
    Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy.
    Norre T; Grimm D; Simonsen U
    Basic Clin Pharmacol Toxicol; 2022 Apr; 130(4):425-438. PubMed ID: 35128801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strength in synergy: Cardiometabolic effects of sacubitril/valsartan in heart failure and diabetes.
    Seferović PM; Polovina M; Seferović J; Rosano G
    Int J Cardiol; 2023 Jan; 371():293-294. PubMed ID: 36115444
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Application of Sacubitril/Valsartan in Heart Failure.
    Liu X; Zhong L
    Am J Ther; 2021 Apr; 28(4):e511-e513. PubMed ID: 33852477
    [No Abstract]   [Full Text] [Related]  

  • 14. Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study.
    Januzzi JL; Omar AMS; Liu Y; Murphy S; Butler J; Felker GM; Piña IL; Ward J; Solomon S; Contreras J
    Circulation; 2022 Nov; 146(21):1638-1640. PubMed ID: 36183276
    [No Abstract]   [Full Text] [Related]  

  • 15. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
    Rodgers JE
    Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/Valsartan and Rhabdomyolysis: Reanalysis of a Potential Safety Signal.
    Woods RH
    Am J Cardiol; 2022 Jun; 173():145-146. PubMed ID: 35430084
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril/Valsartan (Entresto) for Heart Failure.
    Cheng J
    Am Fam Physician; 2016 Oct; 94(8):611-612. PubMed ID: 27929235
    [No Abstract]   [Full Text] [Related]  

  • 20. Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia.
    Fuzaylova I; Lam C; Talreja O; Makaryus AN; Ahern D; Cassagnol M
    J Pharm Pract; 2020 Oct; 33(5):696-699. PubMed ID: 30776953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.